Outlook Therapeutics receives Overweight rating from Piper Sandler with $4 price target
OTLK•Piper Sandler initiated coverage of Outlook Therapeutics with an Overweight rating and a $4 price target.
Related News

BlackRock declares quarterly dividend of $5.73 on common stock
BLK•

ORIX launches first aircraft leasing fund with approximately 60 billion yen in assets
IX•

Antero Midstream General Counsel Yvette K. Schultz sells $1.02 million in shares
AM•

Emmaus Life Sciences Q3 revenue falls after NIT licensing deal
EMMA•

Grab CFO Peter Henry Oey sells $161,205 of Grab common shares
GRAB•